Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Redbiotec AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner. The portfolio is active in 1 distinct art unit, which suggests a specific focus for the current prosecution cycle, as there is no distribution of work across different technical groups. This concentration allows for a unified prosecution strategy but limits the diversity of examiner perspectives.
GRIZER, CASSANDRA SENN is identified as the busiest examiner for the company. This individual is responsible for 1 busiest examiner pending office action. The alignment between the total pending actions and the workload of this specific examiner indicates that all current activity is centralized under a single point of review. This centralization means the company's immediate patent strategy in this technology area depends entirely on the findings of GRIZER, CASSANDRA SENN. Practitioners should focus on the specific preferences of this individual to anticipate the outcome of the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280908 | VACCINE COMPOSITIONS AND METHODS FOR TREATING HSV | GRIZER, CASSANDRA SENN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280908 | VACCINE COMPOSITIONS AND METHODS FOR TREATING HSV | GRIZER, CASSANDRA SENN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280908 | VACCINE COMPOSITIONS AND METHODS FOR TREATING HSV | GRIZER, CASSANDRA SENN | 1672 | §101§103§112DP | Non-Final OA | — | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRedbiotec AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Cassandra Senn Grizer has the most, with 1 of Redbiotec AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
